Roux-en Y gastric bypass increased the likelihood of nonvertebral fractures, including hip, wrist, and pelvic fractures.
Researchers observed detrimental effects of RYGB on bone turnover, mass, structure, and strength just 6 months postoperatively, and these effects persisted throughout the duration of the 12-month study.
For obese adults with type 2 diabetes, Roux-en-Y gastric bypass surgery is associated with greater weight loss, lower HbA1c, and reduced cardiovascular risk compared with intensive medical diabetes and weight management.
A recent study reported that the risk for suicide and non-fatal self-harm was increased after bariatric surgery.
Roux-en-Y gastric bypass (RYGB) with simultaneous cholecystectomy had a significantly higher complication rate and took more than 1 hour longer than RYGB without cholecystectomy.
Researchers examined the nonvertebral fracture risk in adults with obesity who underwent Roux-en-Y gastric bypass vs adjustable gastric banding.
Severely obese adolescents who underwent gastric bypass surgery experienced significant weight loss that was maintained over long-term follow-up.
Gastric bypass, but not gastric banding, is associated with reduced risk of psoriasis, progression to severe psoriasis, and psoriatic arthritis.
Patients who undergo Roux-en-Y gastric bypass are less likely to die from obesity or other diseases than those who did not undergo the procedure 10 years later.
After Roux-en-Y gastric bypass surgery, variations in rates of diabetes remission are primarily related to differences in the definition of remission and study duration.
A patient came to the clinic to discuss her dizzy spells 4 years after her Roux-en-Y gastric bypass surgery.
The addition of Roux-en-Y gastric bypass to lifestyle-medical management is associated with improved achievement of treatment goals in type 2 diabetes.
Gastric bypass surgery is associated with reduced symptoms and neurohormonal responses to hypoglycemia, according to a study published in Diabetes.
An array of changes in protein abundance in skeletal muscle were observed before and after RYGB surgery.
As DiaRem score increases, the proportion of patients experiencing remission decreases.
The temporary 1-year intestinal bypass device with liraglutide boosts weight loss and improves diabetes control.
Compared with a rigorous lifestyle and medical intervention, gastric bypass surgery led to greater remission of type 2 diabetes.
Gastric bypass is linked to reduced mortality in patients aged older than 35.
Patients who underwent gastric bypass reported improved well-being, but symptoms and hospitalizations were high after the procedure.
A decrease was seen after gastric bypass for patients with type 2 diabetes, but not with normal glucose tolerance.
Surgery associated with significantly lower plasma lipids, CV risk, medication use vs. drug therapy.
Researchers found blood alcohol levels were doubled in women who had gastric bypass.
A 3.5-fold AMPK activity increase and 50% drop in oxidative stress 3 months after surgery.
Combining Roux-en-Y gastric bypass with a drug that targets the serotonin C receptor, like lorcaserin, may increase weight loss after the procedure.
Researchers saw a 50% decrease in oxidative stress.
Weight loss, improvements in metabolic parameters better with duodenal switch in patients with BMIs exceeding 50.
RYGB predicts insulin therapy cessation early after surgery, independent of weight.
Obese patients who underwent bariatric surgery had lower mortality rates compared with those who did not undergo the procedure.
Laparoscopic gastric bypass surgery has a complication and mortality rate comparable to some of the safest, most commonly performed procedures.
Gastric bypass helps patients lose more weight than gastric banding but also has a higher risk for complications and hospitalizations.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- New Romosozumab BLA Includes Data from Additional Osteoporosis Trials
- Impact of Maternal Diabetes on Outcomes in Very Preterm, Very Low-Birth-Weight Infants
- Age-Related Differences in Manifestation of Cushing Disease Identified
- International Group Develops Best Practices for Drug Packaging